Colorectal cancer: who works on it

One card per institution. Filter by target, by country, or show only institutions in EU-13 (Horizon Europe widening) countries.

• All targets
• TP53 6
• KRAS 57
• PD-1 108
• BRAF 36
• EGFR 32
• PD-L1 26
• PI3K 2
• STAT3 0
• CTNNB1 1
• AKT 0
• RAS 31
• HER2 38
• mTOR 1
• MAPK 1
• VEGF 14
• ERK 0
• STING 0
• NRF2 0
• PPAR 0
• CTLA-4 16
• HIF-1 0
• COX-2 5
• JNK 0
• AMPK 0
• MYC 0
• PTEN 1
• YAP 0
• GPX4 0
• NRAS 8
• IL-6 0
• JAK 0
• MET 7
• PARP 1
• CXCR4 0
• TNF 0
• NLRP3 0
• BCL-2 0
• HSP90 0
• PIK3CA 2
• GLP-1 1
• HDAC 2
• METTL3 0
• MEK 1
• CDK4/6 2
• CD47 1
• BRCA1 1
• FGFR 0
• NTRK 1
• B7-H3 5
• EZH2 0
• FAK 1
• HMGB1 0
• TROP2 4
• MUC1 2
• ATM 2
• IDO1 1
• IL-1 0
• PCSK9 3
• PINK1 0
• SHP2 0

EU-13 is a filter, not a ranking: it only narrows the list.

3 of 3+ institutions, ordered by recent publications and open trials. This is not a ranking of quality.

Terminated, withdrawn and suspended trials with the reason the sponsor gave in the registry, quoted word for word.

• Terminated

  Regorafenib in Combination With Pembrolizumab or Pembrolizumab for MSI-H Colorectal Cancer

  NCT06006923· Anwaar Saeed· Updated 20 Jan 2026

  “Terminated per directive from Bayer due to funding.”Registry text, quoted unchanged. Source

• Terminated

  A Study of Fruquintinib in Combination With Tislelizumab in Advanced Solid Tumors

  NCT04577963· Hutchmed· Updated 14 Jul 2025

  “At the time of study termination, both fruquintinib and tislelizumab are commercially available in the United States.”Registry text, quoted unchanged. Source

• Terminated

  Surufatinib in Combination With Tislelizumab in Subjects With Advanced Solid Tumors

  NCT04579757· Hutchmed· Updated 8 May 2025

  “Study terminated by sponsor”Registry text, quoted unchanged. Source

• Terminated

  Study to Test the Safety and Tolerability of PF-07062119 in Patients With Selected Advanced or Metastatic Gastrointestinal Tumors.

  NCT04171141· Pfizer· Updated 16 Jan 2025

  “Study was terminated due to strategic considerations and not due to safety.”Registry text, quoted unchanged. Source

• Withdrawn

  Tislelizumab Combined With Fruquintinib for Metastatic pMMR/MSS Colorectal Cancer

  NCT05690035· Sun Yat-sen University· Updated 9 Jul 2024

  “Due to slow patient recruiting. No patients were enrolled 12 months after study initiation.”Registry text, quoted unchanged. Source

• Withdrawn

  A Phase lb/ll, Open Label, Single Arm Study With Olinvacimab and Capecitabine in mCRC Patients (OLCAP)

  NCT04751955· Korean Cancer Study Group· Updated 31 Oct 2023

  “This clinical trial was not finally approved by the Korea FDA.”Registry text, quoted unchanged. Source

Trials whose registry record says individual participant data (IPD) will be shared.

• Phase I/II Study of the Anti-Programmed Death Ligand-1 Durvalumab Antibody (MEDI4736) in Combination With Olaparib and/or Cediranib for Advanced Solid Tumors and Advanced or Recurrent Ovarian, Triple Negative Breast, Lung, Prostate and Colorectal Can...

  NCT02484404· National Cancer Institute (NCI)· Source

Find publications on this disease by a MeSH method term, for example a sequencing or imaging method.

• Single-Cell Analysis 133
• Organoids 108
• Mendelian Randomization Analysis 49
• CRISPR-Cas Systems 34
• Gene Expression Profiling 337
• Sequence Analysis, RNA 29
• Whole Genome Sequencing 22
• Exome Sequencing 26
• Proteomics 107
• Metabolomics 92
• Mass Spectrometry 42
• Flow Cytometry 113
• Immunohistochemistry 208
• Liquid Biopsy 36
• Circulating Tumor DNA 119
• Xenograft Model Antitumor Assays 432
• Positron-Emission Tomography 38
• Magnetic Resonance Imaging 196
• Machine Learning 210
• Deep Learning 142
• Cohort Studies 316
• Genome-Wide Association Study 65

• Automated Tissue Classification and Candidate Biomarker Feature Extraction in Mass Spectrometry Imaging Based on Interpretable Deep Learning Algorithm.

  Rapid Commun Mass Spectrom, Nov 2026

• Intraoperative margin assessment in colorectal cancer via AI-enhanced multiphoton microscopy.

  J Biomed Opt, Oct 2026

• FCVGAN: A Novel Generative Framework Integrating Fuzzy C-Means Clustering with Conditional VAE-GAN for Polyp Segmentation.

  Sensors (Basel), Sept 2026

• RareCode: An Unsupervised Deep Learning Framework for Anomaly Detection in Colorectal Cancer Histopathological Images.

  J Vis Exp, Sept 2026

• From cell counts to cellular interactions: Cu-Cyto and the co-localization index as a spatial framework for the tumor immune microenvironment of rectal cancer.

  Int J Clin Oncol, Sept 2026

• Colorectal Lesion diagnosis using transformer and deep learning with multiscale feature interface.

  PLoS One, Sept 2026

• A Vision Transformer- and Radiomics-based Model for Predicting Liver Metastasis-Free Survival in Patients with Rectal Cancer.

  Radiol Imaging Cancer, Sept 2026

• Real-world clinical impact of implementing and updating a deep learning-based automatic contouring system in rectal cancer radiotherapy.

  J Appl Clin Med Phys, Sept 2026

• DNAmBERT: a transformer-based model for non-invasive cancer diagnosis using DNA sequence and methylation data.

  Brief Bioinform, Sept 2026

• A nomogram integrating multi-channel 2.5D twins-SVT deep learning and radiomics for predicting disease-free survival in patients with locally advanced rectal cancer following primary total mesorectal excision.

  Eur J Radiol, Aug 2026

See which targets of this disease your abstract mentions, and go to the people working on them.